Talniflumate
Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. It also increases survival in a cystic fibrosis mouse model of the distal intestinal obstructive syndrome. (In Vivo) :Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction.
Product Specifications
CAS Number
66898-62-2
Product Name Alternative
Talniflumate
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : 62.5 mg/mL (150.85 mM)
Smiles
FC (F) (F) c1cccc (Nc2ncccc2C (=O) OC2OC (=O) c3ccccc23) c1
Molecular Formula
C21H13F3N2O4
Molecular Weight
414.33
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-[[3- (Trifluoromethyl) phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cathepsin D (Tumor Marker) (CTSD/3082), CF640R conjugate, 0.1mg/mL
